Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;73(9):775-778.
doi: 10.1016/j.rec.2020.05.015. Epub 2020 May 30.

Clinical course of COVID-19 in pulmonary arterial hypertension patients

[Article in English, Spanish]
Jorge Nuche  1 , Carmen Pérez-Olivares  2 , Teresa Segura de la Cal  2 , Carmen Jiménez López-Guarch  3 , Fernando Arribas Ynsaurriaga  3 , Pilar Escribano Subías  4
Affiliations

Clinical course of COVID-19 in pulmonary arterial hypertension patients

[Article in English, Spanish]
Jorge Nuche et al. Rev Esp Cardiol (Engl Ed). 2020 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Possible explanations for the benign course of COVID-19 in PAH patients. Impaired viral entrance to pulmonary cells due to the presence of “tertiary lymphoid tissue” and reduced ACE2 expression. Reduced lung damage due to impaired “vasotonic” properties and to PAH vasodilator treatment, minimizing intrapulmonary shunt. Reduced inflammatory response mediated by ET-1 due to the effect of ERA. ACE2, angiotensin-converting enzyme 2; CCB, calcium-channel blocker; ERA, endothelin receptor antagonist; ET-1, endothelin-1; PDi, phosphodiesterase-5 inhibitor; VD/VC, vasodilatation/vasoconstriction.
See this image and copyright information in PMC

References

    1. Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1286. - DOI - PubMed
    1. Harder E.M., Small A.M., Fares W.H. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir Med. 2020;161:105850. - PubMed
    1. Hemnes A.R., Rathinasabapathy A., Austin E.A. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51:1702638. - PMC - PubMed
    1. Kuba K., Imai Y., Rao S. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879. - PMC - PubMed
    1. Araz O. Current Pharmacological Approach to ARDS: The Place of Bosentan. Eurasian J Med. 2020;52:81–85. - PMC - PubMed

MeSH terms